Roivant Sciences

Biotech holding company Roivant Sciences raised $200M in funding at a whopping $7B valuation

Roivant Sciences has had a bumpy couple of years, but that isn’t stopping investors from pouring more money into the four-year-old company, which aims to one day be a giant parent company for do

Roivant looks to quickly turn the page, starting with a Phase 3 win

A new hormonal therapy designed to treat uterine fibroids called relugolix has finished a Phase 3 study in Japan, and the results are positive. That's welcome news for a SoftBank-backed company based